The therapeutic efficacy of long acting beta2 stimulant in patients with early stage COPD

The therapeutic efficacy of long acting beta2 stimulant in patients with early stage COPD - The efficacy of LABA in early stage COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016046

Enrollment

Registered

2015-01-01

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with early stage COPD screened by medical examination

Interventions

4-week treatment with tiotropium followed by 4-week treatment with indacaterol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)definite diagnosis of COPD 2)given informed consent

Exclusion criteria

Exclusion criteria: 1)patients who are difficlut to perform frequent spirometry 2)patients with glaucoma 3)patients with urinary disturbance due to benign prostate hypertrophy 4)patients who are judged to be unfit to the study

Design outcomes

Primary

Measure	Time frame
Amount of change in FEV1 between pre- and post-treatment	—

Secondary

Measure	Time frame
modified MRC socre, COPD assessment test (CAT), adverse events	—

Countries

Japan

Contacts

Public ContactMasaki Hanibuchi

Tokushima University Hospital Department of Respiratory Medicine and Rheumatology

mhoney@tokushima-u.ac.jp+81-88-633-7127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026